2006-1B / ACT-2 – Alemtuzumab and CHOP in T-Cell Lymphoma (elderly patients)

General information and documents for the clinical trial DSHNHL 2006-1B / ACT-2.

This randomized phase III trial will evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 6 courses of 2-weekly CHOP, versus standard chemotherapy with 2-weekly CHOP alone. This protocol is open to elderly patients (>60 years) with previously untreated systemic peripheral T-cell lymphomas. This study is designed to recruit a total of 274 patients from October 2007 through October 2011, and has been activated in several German as well international clinical centers.

General Information

Publicly available documents

Password protected documents

The following documents are to be used for patients who are treated within the framework of "Integrierte Versorgung" as "Nicht-Studien-Patienten" :

PDF Aufnahmebogen Nicht-Studienpatienten (60 kB, German, 1 page)

PDF Therapiebogen Nicht-Studienpatienten (28 kB, German, 1 page)

PDF Nachsorgebogen Nicht-Studienpatienten (28 kB, German, 1 page)